Elk jaar organiseert de NVTAG een competitie voor de NVTAG prijs (ook wel bekend als de MTA prijs). De winnaar heeft in het voorgaande jaar onderzoek gepubliceerd dat op originele wijze bijdraagt aan de verdere ontwikkeling van onderzoeksmethoden in de MTA. Naast eeuwige roem krijgt de winnaar een geldbedrag van 1,000 Euro met dank aan onze sponsor Bresmed. Hieronder zie je een overzicht van de winnaars van de afgelopen jaren.


2018 Giske Lagerweij
A new selection method to increase the health benefits of CVD prevention strategies European Journal of Preventive Cardiology 2018, 25(6) 642–650

2017 Ben Wijnen
A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy.

2016 Hedwig Blommestein
A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model

2015 Maria Gheorghe
Quality of life and time to death: have the health gains of preventive interventions been underestimated?

2013 Arthur Attema

2012 Aukje van Gestel
van Gestel A, et al. The Role of the Expected Value of Individualized Care inCost-Effectiveness Analyses and Decision Making. Value in Health 2012:13–21.

2010 Ana Bobinac
Bobinac A, et al. Caring for and caring about: Disentangling the family effect and the caregiving effect. Journal of Health Economics 2010; 29: 549-556

2008 Ties Hoomans
Hoomans T et al. Value of information and Value of implementation of an analytic framework to inform resource allocation decisions in metatstatic hormone-refractory prostate cancer. Value in Health 2009; 12; 2; 315-324.

2007 Pieter van Baal
Baal P van, e.a. Unrelated medical care in life years gained and the cost-utility of primary prevention: in search of a ‘perfect’ cost-utility ratio. Health Economics 2007;16: 421-433.

2006 Mandy vd Brink
Brink M van den, e.a.. Cost measurement in economic evaluations of health care: Whom to ask? Medical Care 2004; 42: 740-746.

2005 Silvie van Osch
Osch SMC van e.a. Correcting biases in standard gamble and time trade off utilities. Medical Decision Making 2004; 24: 511-517.

2004 Dennis Stant
Stant A.D. e.a. Cost-effectiveness of the HIT programme in patients with schizophrenia and persistent auditory hallucinations. Acta Psychiatr Scand. 2003;107(5):361-8.

2003 Jan Oostenbrink
Oostenbrink JB e.a. Standardisation of Costs: the Dutch manual for costing in economic evaluations. Pharmacoeconomics 2002; 20(7):443-54.

2002 Karin Visser
Visser K e.a. Duplex scan surveillance during the first year after infrainguinal autologous vein bypass grafting surgery: Costs and clinical outcome compared with other surveillance programs’.J. Vasc. Surg. 2001; 33:123-30.

2001 Maiwenn Al
Al M , e.a. Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty”, Health Econ 2000; 9: 599-609.

2001 Sylvia Jansen
Jansen S et al. Unstable preferences: a shift in valuation or an effect of the elicitation procedure? Med Decis Making 2000; 20: 62-71.

2000 Petra van Enckevort
Van Enckevort PJ, et al. Technology assessment of the Dutch Lung Transplantation Program. Int J Technol Assess Health Care 1998; 14: 344-356.

1999 Hans Severens
Severens JL, et al. Estimating the cost of lost productivity in dyspepsia. Aliment Pharmacol Ther. 1998; 12: 919-923.